CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

Key facts

Study ID

NCT06238765

Run by

CorEvitas

People needed

1500

Starts

2023-12-02

Expected to finish

2099-12-31

Last updated by the study team

2026-06-29

Who can join

Age: 10 and older, up to 15. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• To be eligible to participate in this registry, an individual must meet all the following criteria:
• Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare provider
• Is 10 - 15 years of age at the time of enrollment.
• Subject has initiated or is initiating an enrollment-eligible medication at the time of enrollment

You may not qualify if…

• An individual who meets any of the following criteria will be excluded from participation in the registry:
• Is participating or planning to participate in a blinded clinical trial for an AD drug.
• Is unwilling or unable to provide standing height measurements.

Where it is running

• CorEvitas, LLC — Waltham, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.